Filing summary: PharmAthene, Inc. 2014 Form 10-K
Entity and period: The supplied filing is PharmAthene, Inc.’s annual report for the fiscal year ended December 31, 2014, filed March 11, 2015. It does not appear to be an Altimmune, Inc. filing. The “2014 Q4” metadata refers to the fourth quarter within the annual filing; the report primarily presents full-year results.
Business context and reporting period
PharmAthene was a biodefense development company whose revenue came substantially from U.S. Government contracts. Its programs included liquid anthrax vaccine SparVax, a next-generation lyophilized anthrax vaccine, rBChE for nerve-agent exposure, and Valortim for anthrax. The company had no marketed products or product-sale revenue.
Financial performance and position
| Metric | FY 2014 | FY 2013 | Change / context |
|---|---|---|---|
| Contract revenue | $10.19 million | $17.91 million | Down 43.0% |
| Research and development expense | $9.32 million | $15.29 million | Down 39.2% |
| General and administrative expense | $10.91 million | $13.28 million | Down 18.0% |
| Operating loss | $10.19 million | $10.84 million | Operating margin approximately -100% versus -61% |
| Net loss | $9.96 million | $11.72 million | Net margin approximately -98% versus -65%; FY 2014 loss per share was $0.17 versus $0.23 |
| Cash used in operating activities | $8.47 million | $7.17 million | Operating cash use increased |
| Cash and cash equivalents at year-end | $18.64 million | $10.48 million | Increase largely funded by equity issuance |
| Working capital at year-end | $16.67 million | $7.54 million | Improved year over year |
| Total debt at year-end | Approximately $0.8 million | Approximately $2.8 million | GE Capital facility; remaining term-loan balance due at September 2015 maturity |
FY 2014 financing activities provided $16.73 million, including $18.14 million net proceeds from common-stock sales and $0.68 million from warrant exercises, partially offset by debt repayments. The company issued 10.52 million shares under its at-the-market equity arrangement. Its accumulated deficit was $220.3 million. The filing states cash on hand was expected to fund operations through at least the end of 2015 based on anticipated operating requirements and capital expenditures.
For the fourth quarter of 2014, revenue was $1.83 million, operating loss was $2.62 million, and net loss was $2.63 million.
Material changes versus prior periods
- Revenue fell primarily as BARDA reduced the scope of the SparVax contract and rBChE contract activity declined. SparVax revenue was approximately $8.1 million in 2014 versus $15.5 million in 2013; rBChE revenue was $0.5 million versus $2.4 million.
- Valortim generated $1.0 million of 2014 revenue from delivery under a BARDA order; management did not expect material future program revenue.
- Operating expenses declined, particularly R&D, but continued to exceed revenue. The 2013 net loss included costs associated with a terminated merger with Theraclone.
- Cash increased despite operating cash outflow, principally because of equity financing. Shares outstanding rose to 63.60 million at year-end 2014 from 52.30 million a year earlier.
Outlook, commentary, risks, and unusual items
- Realignment after year-end: On March 9, 2015, the board approved a plan eliminating 23 employees, approximately two-thirds of the workforce, to preserve cash and pursue partners, co-developers, or buyers for biodefense assets while continuing the NIAID contract. Estimated severance was approximately $2 million, substantially payable in 2015. Senior leadership and board composition also changed.
- Government-contract outlook: The September 2014 NIAID contract had approximately $5.2 million of initial base-period funding and a potential total value of up to $28.1 million if technical milestones are met and all eight options are exercised. Options are at NIAID’s discretion. Management expected 2015 revenue to be significantly lower than 2014; additional funding for liquid SparVax, rBChE, and Valortim was not expected.
- SIGA litigation: A January 2015 judgment awarded PharmAthene $194.6 million, including $113.1 million in expectation damages and $81.5 million in interest and specified legal and expert fees, plus post-judgment simple interest. SIGA appealed and PharmAthene cross-appealed; SIGA was in Chapter 11 and had stated it lacked cash to pay the award. The company recorded no receivable or gain, and collection, timing, and ultimate judgment remained uncertain.
- Development and regulatory risks: SparVax remained on FDA clinical hold after concerns about product-lot stability. BARDA had partially terminated/de-scoped its contract, which ended February 28, 2015. Further animal studies, clinical work, manufacturing development, regulatory review, and financing would be needed; approval and commercialization were uncertain.
- Liquidity and debt risks: The GE Capital loan was secured by substantially all assets and matured in September 2015. The company said BARDA’s SparVax de-scoping could potentially be asserted as a loan default, although it had received no default notice. Additional financing might be needed, potentially diluting shareholders.
- Other contingencies: BARDA audited historical indirect costs on the SparVax contract. The company could not determine the amount or timing of any additional recovery, and audit outcomes could affect revenue or repayment obligations.
- Management reported effective disclosure controls and effective internal control over financial reporting at December 31, 2014. Ernst & Young issued unqualified opinions on the financial statements and internal controls.
Key facts investors should verify
- Confirm the issuer identity: this source is PharmAthene, Inc. (ticker PIP), not Altimmune, Inc.
- Track the Delaware appeal, SIGA bankruptcy proceedings, and any developments affecting the enforceability and collectability of the $194.6 million judgment.
- Verify NIAID funding, milestone performance, and whether any discretionary contract options are exercised.
- Review cash burn after the workforce reduction, severance payments, and the timing or refinancing of the GE Capital debt maturity.
- Follow the SparVax clinical hold, BARDA audit resolution, and any partnership or funding developments for the company’s other programs.
- Assess dilution from future equity issuance, outstanding options and warrants, and the effect of reduced staffing on execution of the realignment plan.